Goldman Sachs
May 21, 2026
ConvaTec Plc YTD Growth and FY26 Guidance Update
Single Stock ReportEquitiesHealth Care
ConvaTec reported 4-month organic growth of 4.8% (ex-InnovaMatrix), which was slightly below expectations, but the company reiterated its FY26 guidance.
Key Takeaways
- 1.Management reiterated FY26 guidance of 5-7% organic growth (excluding InnovaMatrix) and >23% adjusted EBIT margins.
- 2.Year-to-date organic growth of +4.8% is considered 'a little light' compared to consensus expectations of +2.8% including InnovaMatrix.
- 3.InnovaMatrix created a -300bps headwind to group organic growth due to structural changes in the US skin substitutes market.
Table of Contents
- By division...
- Valuation methodology
- Key downside risks
- GS Forecast
- Disclosure Appendix
- Ratings, coverage universe and related definitions
Document Preview
Access the Full Report
Get unlimited access to institutional research reports with a 14-day free trial.
Authors
Richard Felton, CFALauren MitchellVisakh Subramaniam
Securities
CTEC.L
Themes
MedTech Growth PhasingUS Skin Substitutes Market Volatility
Regions
EuropeLatin AmericaAsia PacificUnited KingdomUnited States
